Vol 10, No 4 (2024)
Review paper
Published online: 2024-11-25
Current indications for the use of Janus kinase inhibitors in the treatment of juvenile idiopathic arthritis
1
, 2
, 2
DOI: 10.5603/rf.102571
Rheumatology Forum 2024;10(4):184-193.
Abstract
Juvenile idiopathic arthritis (JIA) is a group of heterogeneous conditions whose main manifestation is arthritis of unknown cause and onset in childhood or adolescence. According to current guidelines, patients with a more severe disease course are treated with conventional synthetic and biological diseasemodifying antirheumatic drugs (DMARDs), which significantly improve the long-term sequelae of the disease. However, despite therapeutic advances, many patients still do not achieve an adequate response to therapy.
Janus kinase (JAK) inhibitors are a new group of targeted synthetic DMARDs previously used in adult patients to treat rheumatoid arthritis (RA). Studies on the efficacy and safety of this group of medicines in various subtypes of JIA and other rheumatic diseases in children are under way. Based on clinical trial results to date, two JAK inhibitors, tofacitinib and baricitinib, have been approved to treat selected subtypes of JIA.
This article presents the current knowledge on the efficacy and safety of JIA treatment with JAK inhibitors
and recommendations for their use in JIA.
Keywords: JIAtreatmentJAK inhibitors
References
- Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004; 31(2): 390–392.
- Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019; 71(6): 717–734.
- Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018; 77(6): 819–828.
- Ruperto N, Martini A. Current and future perspectives in the management of juvenile idiopathic arthritis. Lancet Child Adolesc Health. 2018; 2(5): 360–370.
- Brunner HI, Schanberg LE, Kimura Y, et al. PRCSG Advisory Council and the CARRA Registry Investigators. New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2020; 72(11): 1945–1951.
- Ruperto N, Brunner HI, Zuber Z, et al. Pediatric Rheumatology International Trials Organization (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG). Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol Online J. 2017; 15(1): 86.
- Ramanan AV, Quartier P, Okamoto N, et al. JUVE-BASIS investigators, Paediatric Rheumatology International Trials Organisation. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet. 2023; 402(10401): 555–570.
- Olumiant. https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant (24.08.2024).
- Xeljanz. https://www ema europa eu/en/medicines/human/EPAR/xeljanz (24.08.2024).
- Martini A, Lovell DJ, Albani S, et al. Juvenile idiopathic arthritis. Nat Rev Dis Primers. 2022; 8(1): 5.
- Zaripova LN, Midgley A, Christmas SE, et al. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021; 19(1): 135.
- McCurdy D, Parsa MF. Updates in Juvenile Idiopathic Arthritis. Adv Pediatr. 2021; 68: 143–170.
- Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2022; 74(4): 521–537.
- Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019; 71(6): 717–734.
- Opoka-Winiarska V. Nowe perspektywy leczenia młodzieńczego idiopatycznego zapalenia stawów. (New prospects of the management of juvenile idiopathic arthritis). In: Kwiatkowska B. ed. W: Postępy w reumatologii. Red. nauk. Medical Tribune Polska, Warszawa 2023: 17–26.
- Melki I, Frémond ML. JAK Inhibition in Juvenile Idiopathic Arthritis (JIA): Better Understanding of a Promising Therapy for Refractory Cases. J Clin Med. 2023; 12(14).
- Bagri NK, Chew C, Ramanan AV. Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward. Paediatr Drugs. 2023; 25(6): 635–647.
- Ramanan AV, Quartier P, Okamoto N, et al. JUVE-BASIS investigators, Paediatric Rheumatology International Trials Organisation. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet. 2023; 402(10401): 555–570.
- Ruperto N, Brunner HI, Synoverska O, et al. Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021; 398(10315): 1984–1996.
- Brunner HI, Akikusa JD, Al-Abadi E, et al. Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Ann Rheum Dis. 2024 [Epub ahead of print].
- https://rejestry.ezdrowie.gov.pl/rpl/search/public. Rejestr Produktów Leczniczych (24.08.2024).
- Bagri NK, Chew C, Ramanan AV. Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward. Paediatr Drugs. 2023; 25(6): 635–647.
- Choroby nieonkologiczne. https://www.gov.pl/web/zdrowie/choroby-nieonkologiczne (24.08.2024).
